ARTICLE | Clinical News
Subcutaneous semaglutide: Additional Phase IIIa data
October 10, 2016 7:00 AM UTC
Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Subcutaneous semaglutide ( NN9535) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)...